Wall Street Zen Upgrades Atossa Genetics (NASDAQ:ATOS) to Sell

Atossa Genetics (NASDAQ:ATOS) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

ATOS has been the topic of several other research reports. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw started coverage on shares of Atossa Genetics in a report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price target for the company. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Atossa Genetics has a consensus rating of “Hold” and a consensus target price of $20.33.

Atossa Genetics Price Performance

ATOS opened at $2.60 on Friday. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35. The stock has a market capitalization of $25.95 million, a price-to-earnings ratio of -0.84 and a beta of 1.29. The business has a fifty day moving average price of $2.39 and a 200 day moving average price of $4.22.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.07. On average, research analysts anticipate that Atossa Genetics will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. acquired a new stake in Atossa Genetics during the second quarter worth approximately $2,468,000. Renaissance Technologies LLC boosted its holdings in shares of Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after buying an additional 514,175 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Atossa Genetics in the 2nd quarter valued at $381,000. Qube Research & Technologies Ltd grew its position in shares of Atossa Genetics by 357.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after buying an additional 325,340 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.